IRIS Accounts Production v24.3.2.46 10684797 Board of Directors Board of Directors 1.6.23 31.5.24 31.5.24 11/2/2025 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106847972023-05-31106847972024-05-31106847972023-06-012024-05-31106847972022-05-31106847972022-06-012023-05-31106847972023-05-3110684797ns15:EnglandWales2023-06-012024-05-3110684797ns14:PoundSterling2023-06-012024-05-3110684797ns10:Director12023-06-012024-05-3110684797ns10:Director22023-06-012024-05-3110684797ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3110684797ns10:SmallEntities2023-06-012024-05-3110684797ns10:Audited2023-06-012024-05-3110684797ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3110684797ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3110684797ns10:FullAccounts2023-06-012024-05-3110684797ns10:Director32023-06-012024-05-3110684797ns10:Director42023-06-012024-05-3110684797ns10:Director52023-06-012024-05-3110684797ns10:Director62023-06-012024-05-3110684797ns10:RegisteredOffice2023-06-012024-05-3110684797ns5:CurrentFinancialInstruments2024-05-3110684797ns5:CurrentFinancialInstruments2023-05-3110684797ns5:ShareCapital2024-05-3110684797ns5:ShareCapital2023-05-3110684797ns5:RetainedEarningsAccumulatedLosses2024-05-3110684797ns5:RetainedEarningsAccumulatedLosses2023-05-3110684797ns5:ComputerEquipment2023-05-3110684797ns5:ComputerEquipment2023-06-012024-05-3110684797ns5:ComputerEquipment2024-05-3110684797ns5:ComputerEquipment2023-05-3110684797ns5:UnlistedNon-exchangeTradedns5:CostValuation2023-05-3110684797ns5:ProvidedReleasedInPeriodProvisionsForImpairmentInvestmentsns5:UnlistedNon-exchangeTraded2024-05-3110684797ns5:UnlistedNon-exchangeTradedns5:CostValuation2024-05-3110684797ns5:UnlistedNon-exchangeTraded2024-05-3110684797ns5:UnlistedNon-exchangeTraded2023-05-3110684797ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-05-3110684797ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-3110684797ns5:Non-currentFinancialInstruments2024-05-3110684797ns5:Non-currentFinancialInstruments2023-05-3110684797ns5:RetainedEarningsAccumulatedLosses2023-05-3110684797ns5:RetainedEarningsAccumulatedLosses2023-06-012024-05-311068479712023-06-012024-05-31
REGISTERED NUMBER: 10684797 (England and Wales)












CARUS ANIMAL HEALTH LIMITED

Financial Statements

for the Year Ended 31 May 2024






CARUS ANIMAL HEALTH LIMITED (REGISTERED NUMBER: 10684797)






Contents of the Financial Statements
for the Year Ended 31 May 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CARUS ANIMAL HEALTH LIMITED

Company Information
for the Year Ended 31 May 2024







Directors: K Hattori
T Sakakibara
T Takai
H J Wilder
R E Long
I Maeda





Registered office: Castle Court
41 London Road
Reigate
Surrey
RH2 9RJ





Registered number: 10684797 (England and Wales)





Auditors: Xeinadin Audit Limited
12 Conqueror Court
Sittingbourne
Kent
ME10 5BH

CARUS ANIMAL HEALTH LIMITED (REGISTERED NUMBER: 10684797)

Balance Sheet
31 May 2024

31/5/24 31/5/23
Notes £    £    £    £   
Fixed assets
Tangible assets 4 3,681 3,172
Investments 5 - 2,307,032
3,681 2,310,204

Current assets
Debtors 6 656,116 677,886
Cash at bank 1,461,926 1,327,725
2,118,042 2,005,611
Creditors
Amounts falling due within one year 7 479,013 687,731
Net current assets 1,639,029 1,317,880
Total assets less current liabilities 1,642,710 3,628,084

Capital and reserves
Called up share capital 32,098,822 25,670,830
Retained earnings 9 (30,456,112 ) (22,042,746 )
Shareholders' funds 1,642,710 3,628,084

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 February 2025 and were signed on its behalf by:




R E Long - Director



T Takai - Director


CARUS ANIMAL HEALTH LIMITED (REGISTERED NUMBER: 10684797)

Notes to the Financial Statements
for the Year Ended 31 May 2024

1. Statutory information

Carus Animal Health Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Fixtures and fittings - 20% on reducing balance
Computer equipment - 20% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The directors and management are not aware of any material uncertainties, which may cast doubt on the company's ability to continue as a going concern. The shareholders have expressed their continuing support for the company as at the balance sheet date and for the foreseeable future.

3. Employees and directors

The average number of employees during the year was 12 (2023 - 9 ) .

CARUS ANIMAL HEALTH LIMITED (REGISTERED NUMBER: 10684797)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

4. Tangible fixed assets
Computer
equipment
£   
Cost
At 1 June 2023 3,695
Additions 2,366
Disposals (1,598 )
At 31 May 2024 4,463
Depreciation
At 1 June 2023 523
Charge for year 792
Eliminated on disposal (533 )
At 31 May 2024 782
Net book value
At 31 May 2024 3,681
At 31 May 2023 3,172

5. Fixed asset investments
Unlisted
investments
£   
Cost
At 1 June 2023 2,307,032
Impairments (2,307,032 )
At 31 May 2024 -
Net book value
At 31 May 2024 -
At 31 May 2023 2,307,032

6. Debtors
31/5/24 31/5/23
£    £   
Amounts falling due within one year:
VAT 157,141 279,370
Prepayments and accrued income 495,845 395,279
652,986 674,649

Amounts falling due after more than one year:
Amounts owed by group undertakings - 451
Other debtors 3,130 2,786
3,130 3,237

Aggregate amounts 656,116 677,886

CARUS ANIMAL HEALTH LIMITED (REGISTERED NUMBER: 10684797)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

7. Creditors: amounts falling due within one year
31/5/24 31/5/23
£    £   
Trade creditors 185,681 466,736
Social security and other taxes 27,188 22,873
Other creditors 36,752 12,485
Accruals and deferred income - 8,000
Accrued expenses 229,392 177,637
479,013 687,731

8. Leasing agreements
At the year end the company had total commitments under operating leases of £35,995 (2023 - £15,323) in relation to office space.

9. Reserves
Retained
earnings
£   

At 1 June 2023 (22,042,746 )
Deficit for the year (8,413,366 )
At 31 May 2024 (30,456,112 )

10. Disclosure under Section 444(5B) of the Companies Act 2006

The Report of the Auditors was unqualified.

Samuel Ketcher FCCA (Senior Statutory Auditor)
for and on behalf of Xeinadin Audit Limited

11. Post balance sheet events

After the balance sheet date, a further £543,504 was invested into the subsidiary company, which was subsequently disposed of on 12 August 2024 for consideration of £8. A loss on disposal was recognised as a result, totalling £543,496.

12. Ultimate controlling party

The ultimate controlling party is Kyoritsu Holdings Corporation.

The company is a subsidiary of Kyoritsu Holdings Corporation. The address of the parent company's registered office is 6-5, 1-chome, Kudan-minami, Chiyoda-ku, Tokyo 102-0074 Japan.